Roseburia intestinalis
Selected indexed studies
- Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. (Gut, 2023) [PMID:37491158]
- Roseburia intestinalis-derived butyrate alleviates neuropathic pain. (Cell Host Microbe, 2025) [PMID:39706182]
- Roseburia intestinalis sensitizes colorectal cancer to radiotherapy through the butyrate/OR51E1/RALB axis. (Cell Rep, 2024) [PMID:38412097]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. (2023) pubmed
- Roseburia intestinalis-derived butyrate alleviates neuropathic pain. (2025) pubmed
- Roseburia intestinalis sensitizes colorectal cancer to radiotherapy through the butyrate/OR51E1/RALB axis. (2024) pubmed
- Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn's disease. (2022) pubmed
- Roseburia intestinalis: A possible target for vascular calcification. (2024) pubmed
- Roseburia intestinalis-derived extracellular vesicles ameliorate colitis by modulating intestinal barrier, microbiome, and inflammatory responses. (2024) pubmed
- Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species. (2021) pubmed
- Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity. (2023) pubmed
- Gut bacteria-driven homovanillic acid alleviates depression by modulating synaptic integrity. (2024) pubmed
- Roseburia intestinalis-derived inosine improves intestinal motility by activating TGF-β1/p-Smad3/Transgelin signaling axis. (2025) pubmed